NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ:AMLX) concerning possible violations of federal securities laws.
On November 9, 2023, AMLX announced 3Q 2023 results, including 3Q GAAP earnings-per-share, missing consensus estimates by $0.12. On an earnings call the same day, management stated that the number of new patients starting treatment with its approved drug Relyvrio for amyotrophic lateral sclerosis (a/k/a Lou Gehrig's Disease) was "steady" despite the increase in "discontinuations" of treatment after six months. An ...